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endoscopic disease recurrence, according to the Rutgeerts score (graded as  i2).
CRP and fCal were measured and the respective performance and usefulness of
both surrogate markers with respect to the presence and severity of postoperative
endoscopic disease recurrence were assessed by computing correlations, sensitiv-
ity, specificity and predictive values at adjusted cutoffs and also tests operating
characteristics.
RESULTS: A moderate (i2) and a severe ( i3) endoscopic recurrence was
observed in 18 and 36 patients, respectively. FCal concentrations differed sig-
nificantly in patients experiencing evidences for endoscopic recurrence when
compared with those in endoscopic remission (mean  SEM 484.3  71 g/g
vs 118  17 g/g; p50.0001). The area under the ROC curve (AUROC) to
discriminate between patients in endoscopic remission and recurrence was 0.85
for fCal and lower 0.70 for CRP. The best cutoff point for fCal to distinguish
between endoscopic remission and recurrence after surgery was 100 mg/g, as
determined by the ROC curve and its sensitivity, specificity, positive and negative
predictive values as well as overall accuracy were 93 %, 57 %, 66 %, 89 % and 74
%, respectively. In our cohort, fCal concentrations lower than 100 mg/g would
allow with a high accuracy to avoid colonoscopy in almost 31 % of patients.
CONCLUSION: Measurement of fCal concentrations may be a promising and
useful tool for monitoring CD patients after ileocolonic resection. Patients with a
concentration of fCal below 100 mg/g are highly likely to be exempt of endoscopic
recurrence and therefore fCal measurement in CD patients who had undergone
surgery would get some help in making decision for colonoscopy.
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INTRODUCTION: The presence of endoscopic remission (ER) in patients with
ulcerative colitis (UC) predicts better outcome with fewer relapses and colectomy
rates. However, there is scarce data on the additive prognostic value of histolo-
gical and biological activity among patients with both clinical and endoscopic
remission (complete remission).
AIMS & METHODS: To assess the prognostic value of histological and biolo-
gical activity in UC patients with clinical and endoscopic remission.
METHODS: Prospective observational study including 77 UC patients in clinical
and endoscopic remission from 2 referral centres. Clinical remission was defined
as clinical Mayo score53 and no blood in the stools. Biological activity was
assessed with C-reactive protein haemoglobin and albumin levels, and by leuko-
cyte, and platelet counts. ER was defined as a Mayo endoscopic subscore (MES)
of 0-1. Histological activity was assessed according to Geboes score (GS).
Histological activity was defined as GS3.1 (neutrophils in the epithelium).
Patients were followed up after the endoscopy for 12 months. Clinical relapse
(CR) was defined as a clinical Mayo score 3. Univariate and multivariate
analyses were performed to assess predictors of CR.
RESULTS: Baseline characteristics are summarized in Table 1. During follow
up, 21 patients relapsed (9/27 patients with MES grade 1 and 12/50 with MES
grade 0; P¼0.38), but no colectomies occurred. A GS3.1 was present more
often in patients with MES 1 than in patients with MES 0 (48 vs. 14%;
P¼0.002). CR was more frequent among patients with GS3.1 (43 vs. 20%;
P¼0.034). After adjusting for endoscopic activity, a GS3.1 remained as an
independent risk factor for CR (OR 3.1 (95% CI 1.03-9.09), P¼0.043).
Patients with basal plasmacytosis presented numerically more CR, but differ-
ences were not statistically significant (19 vs. 11%; P¼0.45). None of the demo-
graphic and biological variables included were predictive for CR (Table 1).
Baseline characteristics
All patients
(n¼77)
No relapsers
(n¼56)
Relapsers
(n¼21) P
Female (%) 27 (35) 21 (38) 6 (28) 0.47
Median (IQR) age (years) 51 (41-60) 51 (42-58) 50 (37-66) 0.86
Median (IQR) disease
duration (years)
11 (6-18) 12 (9-20) 8 (2-15) 0.06
Montreal classification(%):
E1/E2/E3
13/39/25(17/51/32) 7/29/20(13/52/35) 4/13/4(19/62/19) 0.75
C reactive protein (mg/L):
median(IQR)
1.2 (0.9-2.7) 1.2 (0.7-2.5) 1.5 (1-3.6) 0.09
Hemoglobin (g/dL):median(IQR) 14.2 (13.2-15.4) 14.5 (13.2-14.5) 14.1 (13.3-15.6) 0.89
WBC (10**9/L): (IQR) 5.9 (5-7.9) 6.0 (4.9-8) 5.7 (5.1-6.9) 0.62
Platelets (10**9/L):median(IQR) 241 (211-295) 249 (212-300) 232 (209-263) 0.37
Albumin (g/L):median(IQR) 46 (43-47) 46 (42-47) 46 (44-47) 0.66
CONCLUSION: In a prospective cohort, histological activity defined as GS
3.1 predicts CR at 1 year among patients with both clinical and endoscopic
remission.
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INTRODUCTION: Fibrostenosing Crohn’s disease (CD) leads to stricture for-
mation and bowel obstruction and is the main indication for surgery. A strictur-
ing phenotype is associated with increased healthcare costs, increased morbidity
and a worse quality of life. It is often difficult to differentiate inflammation from
fibrosis using currently available imaging modalities, and no investigation can
predict the future risk of stricture formation. The development of non-invasive
biomarkers of fibrostenosing CD would represent a significant clinical advance.
MicroRNAs (miRNAs) inhibit protein translation and thereby co-ordinate gene
expression networks. MiRNAs are also present in the circulation, where they are
resistant to degradation and can act as accurate biomarkers of disease. Our lab
has recently demonstrated through targeted assays that the expression of the
miR-29 family is reduced in the mucosa overlying stricture and in the serum of
patients with a stricturing phenotype (SCD). These data suggest that miRNAs
may act as biomarkers of SCD (Nijhuis et al 2014).
AIMS & METHODS: In this study we aimed to explore the potential of serum
miRNAs as biomarkers of fibrostenosing CD. Profiling of RNA isolated from
serum was performed by qPCR array and used to identify miRNAs associated
with SCD (n¼6) relative to inflammatory CD (n¼11) and healthy controls (n¼5).
Differentially expressed miRNAs were subsequently validated by single qPCR
assay in an independent cohort of CD patients (SCD n¼35; inflammatory n¼26;
and penetrating n¼19) and healthy controls (n¼10).
RESULTS: A supervised modeling approach indicated that the SCD patients
had a unique serum miRNA signature. In this model miR-19a-3p and 19b-3p
contributed most strongly to the separation of SCD patients and inflammatory
CD patients; changes in miR-29a-3p and 29c-3p also contributed, albeit to a
lesser extent. Subsequent qPCR validation in an independent cohort demon-
strated a significant reduction in miR-19a-3p and 19b-3p in SCD patients relative
to inflammatory and penetrating CD groups (i.e. non-stricturing CD). In this
cohort, stepwise linear regression confirmed that the association of the miRNAs
with SCD was not affected by confounding factors, e.g. age, smoking status,
disease duration etc. Levels of miR-19a-3p and 19b-3p also remained low in
SCD patients following surgical resection.
CONCLUSION: We have demonstrated that miR-19a-3p and 19b-3p in serum
are novel predictors of fibrostenosing CD. SCD was associated with low levels of
miR-19a-3p and 19b-3p. The levels remained low in SCD patients after surgical
resection indicating that miR-19a-3p and 19b-3p are markers of an SCD pheno-
type, and not merely the presence of stricture at the time of sampling. A long-
itudinal study is required to determine whether a reduction in serum miR-19
levels predates the development of stricture.
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INTRODUCTION: Tumor necrosis factor (TNF) inhibition is central to the
therapy of inflammatory bowel diseases (IBD). However, the durability and
efficacy of this blockade hasn’t been well studied and a better understanding is
crucial for the prognosis of long-term treatment and decision making in case of
loss of response (LOR) to these costly anti-TNF agents. Besides the presence of
antibodies against the drug and serum trough levels additional tests to predict
LOR are needed.
AIMS & METHODS: Consecutive IBD Patients receiving anti-TNF therapy
(infliximab (IFX) or adalimumab) from Bern University Hospital were identified
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and followed prospectively. Patient whole blood was stimulated with a dose-
titration of either human TNF or the TLR agonist lipopolysaccharide (LPS)
followed by flow cytometry. Median fluorescence intensity of CD62L on the
surface of granulocytes was quantified by surface staining with fluorochrome
conjugated antibodies against CD33 and CD62L. Logistic curves of these data
permit the calculation of EC50 or the concentration of TNF required to induce a
50% shedding of surface CD62L [Patuto et al, DDW 2011]. The change in EC50
following the anti-TNF agent infusion, was used to predict the in vivo response
to the anti-TNF agent. This predicted response was correlated to the clinical
evolution of the patients in order to analyze the ability of this test to identify
LOR.
RESULTS: We collected prospective clinical data and 2 blood samples, before
and after anti-TNF agent administration, on 33 IBD patients, 25 Crohn’s disease
and 8 ulcerative colitis patients (45% females) between June 2012 and November
2013. The assay showed a functional blockade (PFR) for 22 patients (17 CD and
5 UC) whereas 11 (8 CD and 3 UC) had no functional response (NR). Selected
clinical characteristics between predicted PFR and NR are compared below
(Table). Among the 22 Patients with PRF, only 1 patient was a clinical non
responders (LOR to IFX), based on clinical prospective evaluation by IBD gas-
troenterologists (PJ, FS and AJM), and among the 11 predicted NR, 3 had no
clinical LOR. Sensitivity of this test was 95% and specificity 73% and AUC
adjusted for age and gender was 0.81. During follow up (median 10 months,
range 3-15) 8 ‘‘hard’’ outcomes occurred (3 medic. flares, 4 resections and 1
new fistula) 2 in the PFR and 6 in the NR group (25% vs. 75%; p50.01).
Predicted
responders
(N¼22)
Predicted
non responders
(N¼11) p value
Age (years þ/-SD) 34.8 (þ/-11) 31 (þ/- 11) 0.35
Clinical LOR: No/partial/complete 68%/27%/1% 27%/27%/46% 0.01
Perianal 41% 12% 0.15
Dis. Dur. start IFX (years þ/-SD) 6.9 (þ/- 6) 3.6 (þ/- 4) 0.07
interval reduction needed 23% 73% 5 0.01
Smokers 33% 36% 0.684
CONCLUSION: CD62L (L-Selectin) shedding is the first validated test of func-
tional blockade of TNF alpha in anti-TNF treated IBD patients and will be a
useful tool to guide medical decision on the use of anti-TNF agents. Prospective
comparative studies with antibodies against the drug and trough levels are
ongoing.
Disclosure of Interest: P. Juillerat Lecture fee(s) from: AbbVie, Merck Sharp &
Dohme and Vifor, Consultancy for: AbbVie, Merck Sharp & Dohme and UCB,
P. Andrew: None declared, J. Macpherson: None declared, E. Slack: None
declared, J. Cahenzli: None declared, F. Seibold Consultancy for: AbbVie,
Merck Sharp & Dohme, UCB, K. McCoy: None declared, A. Macpherson:
None declared
OP138 THE NEW FECAL MARKERMATRIX METALLOPROTEASE-9 IS
MORE SENSITIVE FOR DIAGNOSING ULCERATIVE COLITIS AND
POUCHITIS AND FOR DIFFERENTIATING THEM FROM CROHN’S
DISEASE THAN FECAL CALPROTECTIN
K. Farkas1,*, Z. Saro´di1, A. Ba´lint1, I. Fo¨ldesi1, G. La´za´r2, Z. Simonka2,
L. Tiszlavicz3, M. Szu
00
cs4, T. Nya´ri4, F. Nagy1, Z. Szepes1, R. Bor1,
A. Annaha´zi1, R. Ro´ka1, T. Wittmann1, T. Molna´r1
1First Department of Medicine, 2Department of Surgery, 3Department of
Pathology, 4Department of Medical Physics and Informatics, University of Szeged,
Szeged, Hungary
Contact E-mail Address: farkas.klaudia@gmail.com
INTRODUCTION: Inflammatory biomarkers that correlate with enteric inflam-
mation would be beneficial for monitoring the course of disease and targeting
treatment in patients with inflammatory bowel disease (IBD). Only limited data
are available about the diagnostic accuracy of fecal matrix metalloprotease
(MMP)-9 in IBD.
AIMS & METHODS: The aims of our prospective study was to assess the
diagnostic accuracy of fecal MMP-9 in patients with active Crohn’s disease
(CD), ulcerative colitis (UC) and pouchitis assessed by clinical, endoscopic and
histological scores and to compare the diagnostic accuracy of fecal MMP-9 and
fecal calprotectin (CP) in IBD. Stool and blood samples were collected in 50 CD,
54 UC and 34 ileal pouch-anal anastomosis patients before control endoscopy.
Biopsies were taken for histology. The activities of CD, UC and pouchitis were
defined with the use of clinical, endoscopic and histological activity scores
(CDAI, partial Mayo score, PDAI, SES-CD, Mayo endoscopic subscore,
D’Haens and Riley score). Fecal CP and MMP-9 levels were quantified by use
of enzyme-linked immunosorbent assay.
RESULTS: ActiveCD,UCand pouchitiswas detected in 38%, 54%and 29%of the
patients. Significant correlation was revealed between fecal CP and the clinical activ-
ities of CD and UC, and between fecal CP and the endoscopic activity of UC and
pouchitis. No correlation was found between fecal CP and the other examined
activity scores in CD, UC and pouchitis. Fecal MMP-9 did not correlate with any
of the activity indices of CD, however strong association was shown between fecal
MMP-9 and clinical, endoscopic and histological activities of bothUCandpouchitis.
CONCLUSION: This is the first study assessing the diagnostic accuracy of
MMP-9 in different types of IBD. Our results showed that fecal MMP-9 has
an exclusively high specificity in the detection of active UC and pouchitis. These
non-invasive methods help assessing intestinal inflammation and also differen-
tiating between CD and UC.
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INTRODUCTION: Genetic markers, as compared to serologic markers, could
theoretically be superior for predicting inflammatory bowel disease (IBD) out-
comes as genes are not affected by disease activity and are stable over time.
Genetic polymorphisms of Fc gamma receptors (FcR) may affect the efficacy
of immunoglobulin (Ig)-based therapies by influencing the affinity of Ig to the
receptors. We therefore hypothesized that these could facilitate prediction of
sustained remission after anti-TNF discontinuation in IBD.
AIMS &METHODS:We aimed to investigate if polymorphisms in the FcRIIa,
FcRIIIa and FcRIIIb genes are predictive of sustained clinical remission (SCR)
after infliximab (IFX) cessation for clinical remission in Crohn’s disease (CD)
patients. In this single-center retrospective study, 100 CD patients who discon-
tinued IFX for clinical remission (luminal CD, n¼57) were identified from an
electronic database. The majority of patients (n¼84) continued on immunomo-
dulators. SCR was defined as maintained disease remission without the need to
re-introduce medical therapy (biologicals, corticosteroids, thiopurines or metho-
trexate) or surgery until the end of follow up. The functional polymorphisms
131H/R in FcRIIa (n¼84), 158V/F in FcRIIIa (n¼91) and NA1/NA2 in
FcRIIIb (n¼87) were analyzed by PCR-RFLP / TaqMan.
RESULTS: With a median follow up of 9.7 (IQR 8-11.5) years, 52/100 patients
had SCR. Univariate (Log-Rank) analysis revealed no significant association of
the investigated polymorphisms with either SCR or relapse after IFX disconti-
nuation for clinical remission. Nevertheless, individual analysis of patients with
luminal CD interestingly showed that NA2/NA2 homozygosity in FcRIIIb was
associated with increased risk for relapse (HR:2.4, 95%CI:1.1-5.3, p¼0.021).
Multiple COX regression analysis identified NA2/NA2 homozygosity as an inde-
pendent variable predicting relapse after IFX cessation (HR:2.3, 95%CI:1.03-5.1,
p¼0.043).
CONCLUSION: We identified that FcRIIIb NA2/NA2 homozygosity is an
independent factor predicting relapse in patients with luminal CD who discon-
tinue IFX for clinical remission. The lack of NA1 variant, which shows a higher
affinity for IgG1 and probably leads to a more efficient downstream effects
(antibody-dependent cellular cytotoxicity), may therefore predispose to relapse
after IFX cessation in patients with luminal CD. Of note, NA1/NA1 homozyg-
osity was previously found to be associated with higher biological response to
IFX in IBD patients.1
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INTRODUCTION: Pharmacological treatment of ulcerative colitis (UC) is tra-
ditionally divided into treatment of active disease and treatment to maintain
remission. Recently, targeted therapy for patients at increased risk of a flare,
using biomarkers to detect subclinical disease activity, has been proposed.
The objective of this study was to assess if fecal calprotectin (FC), as a marker for
inflammatory activity, can be used to guide medical intervention, to maintain
remission in patients with UC.
AIMS & METHODS: In this open-label, prospective, controlled study, 91 adult
patients with UC in clinical remission, and under treatment with an oral 5-ASA
agent, were randomized to either an intervention group (n¼51) or a control
group (n¼40). All patients had at least one flare within one year prior to the
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